TVM Capital founded in Germany as Techno Venture Management, opening its first office in Munich.
First fund, TVM I, is raised.
TVM Capital portfolio company Qiagen is the first German company to go public on NASDAQ. TVM Capital was a lead investor in the company.
To offer a higher degree of flexibility to investors, TVM Capital’s fifth fund generation consists of two dedicated industry-specific fund entities — TVM V Life Science Ventures, raised in 2001, and TVM V Information Technology, raised in 2002.
TVM Capital surpasses $1 billion in investment funds raised and under management.
TVM Capital raises EUR240 million for TVM Life Science Ventures VI to focus on biotech and biopharmaceutical investment opportunities in the U.S. and Europe.
TVM Capital Healthcare starts operations in Dubai with TVM Healthcare MENA I, a Shari’a compliant fund focusing on private equity investments in healthcare businesses in the Middle East and North Africa region, as well as India.
TVM Capital Life Science starts operations in the Montreal investment office. An investor syndicate led by Teralys Capital and pharmaceutical company and strategic partner, Eli Lilly and Company invest US$143 million in the first closing of TVM Life Science Ventures VII, a new fund dedicated to investments in the life sciences sector.
TVM Capital announces that its activities in information technology have come to an end, and its investment focus will be exclusively on financing innovation in biopharmaceuticals and medical technologies through its venture capital team based in Munich and Montreal, and investing in innovative and fast growing businesses in healthcare in emerging markets through its private equity team based
TVM Capital Life Science announces the final closing of TVM Life Science Ventures VII at US$ 201.6 million. The fund follows a new and lean investment approach innovating the process of drug development with high capital efficiency while ensuring quality of research and best-in-class processes.
TVM Capital Healthcare Partners conducted the first exit by its TVM Healthcare MENA I fund, divesting ProVita International Medical Center to NMC Health plc (LSE:NMC), and closed TVM Healthcare MENA II, an annex fund to TVM Healthcare MENA I, which is exclusively dedicated to growth capital investments in the existing portfolio.